

QIBA Dynamic Susceptibility Contrast (DSC) Biomarker Committee (BC) Call

Wednesday, November 21, 2018 at 11 AM (CT)

Call Summary

Participants

Bradley Erickson, MD, PhD (Co-Chair) Ona Wu, PhD (Co-Chair) Edward Jackson, PhD

RSNA

Joe Koudelik
Susan Stanfa

Moderator: Dr. Wu

DSC Profile Update

- Profile available to all DSC BC members through Google Drive:
<https://drive.google.com/open?id=0B9fMpfGBABYMfnY5UG83bXJKUnc0dGNBTVFnX0Mxcld0LWRsVlxueFRWU3RRSFI1VWIZNOK>
- Latest Profile updates were reviewed and remaining tasks were discussed
- Section 2: Clinical Context and Claims
 - Placeholders indicate where references are needed
 - Dr. Wu's comments in the Google Doc refer to areas that need to be addressed
 - Dr. Erickson to use reproducibility of data results from his paper to complete Table 1 in Section 2.2: Clinical Interpretation Discussion
- Appendix F: Conformance Checklists - feasibility of requirements for technologists to be evaluated
- Section 3.11.1: Image QA Discussion on Tumor Size
 - Dr. Wu to make text modifications based on "enhancing tumor area"
 - Minimum tumor size requirement = >1 cm area or 25 voxels
 - Tumor margins/diameter more relevant than region of interest (ROI)
 - Erickson's expertise needed for 3.11.2 Specification Table tumor size requirement
- Dr. Wu worked on references using the management tool, Paperpile
- The Claims are based on estimates of perfusion AUC-TN coefficient of variation (wCV) for regions of interest in this size range located in enhancing tumor or normal tissue; feedback on Claims was encouraged
- Attention needed on comments related to ADC in Section 4: Assessment Procedure: MRI Equipment Specifications and Performance
- Consensus needed that Claims issues have been resolved, Assessment and Conformance components to be finished, and then the Profile will be ready for BC approval to release for public comment
- Dr. Wu to make final, direct edits to the Profile technical specifications (as opposed to adding suggestions or comments to the document); Dr. Erickson to work on regions of interest in Section 2.2: Clinical Interpretation Discussion; and Dr. Jackson invited to perform a QIBA high-level review
- ISMRM paper to be discussed during January 9 DSC BC t-con
- Dr. Erickson to attend RSNA Annual Meeting on Nov 25 - 26; Dr. Wu to lead DSC BC breakout session at the Nov 28 QIBA Working Meeting

Next DSC BC Call: Wednesday, December 12, 2018 at 11 AM CT

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join**

simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.